Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The aim of study is to examine the relationship between lipid subfractions, inflammation and
structural-functional properties of the arterial wall in patients with premature coronary
heart disease, to study genetic polymorphisms that determine lipid subfractions concentration
on the functional and morphological properties of the arterial vascular wall in patients with
early coronary heart disease, to study the effect of alirocumab and evolocumab on lipid
subfractions, inflammation and structural-functional properties of arterial wall in patients
with early coronary atherosclerosis and to study the influence of NOS-3 gene expression on
the functional and morphological properties of the arterial vascular wall in the same
patients. Impaired blood fat metabolism and chronic inflammation are intertwined as possible
causes of atherosclerosis. Lipoprotein (a) (Lp (a)) is an important risk factor for coronary
heart disease and a prognostic predictor in patients after myocardial infarction, but recent
research suggests that subtilisin-kexin convertase type 9 (PCSK9) inhibitors are the only
drugs that significantly reduce serum Lp (a) concentration. However, there are no data on the
relationship between Lp (a) values and polymorphisms for Lp (a), indicators of inflammation
and impaired arterial function, and response to treatment with various PCSK9 inhibitors in
patients with early coronary heart disease.